Genocea Biosciences, Inc. is a biopharmaceutical company focused on pioneering novel cancer immunotherapies. It leverages its distinctive ATLAS discovery platform to meticulously profile each patient's CD4+ and CD8+ T cell immune responses against specific targets or antigens, which are identified through next-generation sequencing of their individual tumors. Among its lead clinical-stage candidates is GEN-011, an adoptive T cell therapy currently in Phase 1/2a trials for solid tumors. Also undergoing Phase 1/2a clinical evaluation is GEN-009, an investigational neoantigen vaccine designed to deliver adjuvanted synthetic long peptides corresponding to anti-tumor neoantigens pinpointed by ATLAS. Established in 2006 and based in Cambridge, Massachusetts, the company notably filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts on July 5, 2022.